Featured Companies

Atrin Pharmaceuticals.jpg
Atrin Pharmaceuticals is a private biopharmaceutical company pioneering the discovery & development of proprietary molecules targeting DNA Damage and Response (DDR) pathways to treat a broad spectrum of cancers associated with synthetic lethality and the deregulated DNA Damage Response.
Company Presenter

Dr. Gilad has extensive leadership experience across all phases of drug development. He has an accomplished track record leading Atrin from inception to pre-clinical and moving into the clinical stage. Prior to founding Atrin in 2011, Dr. Gilad had a 13-year academic career, where he has authored numerous high impact scientific articles, including one that demonstrated the importance of the ATR pathway in cancer development and prevention. This breakthrough research was conducted at the University of Pennsylvania. This is the third company that he has set up, the first two having been sold.  

Oren Gilad, Ph.D - President and CEO

Dr. Gilad holds a B.Sc from the Hebrew University, a Ph.D and post-doctorate from University of California at Davis, and a post-doctorate from the University of Pennsylvania.

Diverse Biotech Logo 2019 v2.png
Diverse Biotech is a US-based biopharmaceutical company, focused on medical discoveries and the development of new molecules for the treatment of cancer and other debilitating diseases.   Our focus is on discovering and developing novel therapeutics utilizing cannabidiol (CBD) as a core component and combining it through highly advanced chemistry with other molecules to develop new chemical entities that are theoretically more efficacious and less toxic.  Our initial focus is on hard-to-treat oncologic disorders including glioblastoma and pancreatic cancer, where targeted therapies have proven largely unsuccessful thus far and there is significant unmet need.
Company Presenter
Brian Longstreet is a top-level Senior Healthcare Executive known for strong leadership, innovative thinking, and delivering results.  Mr. Longstreet is a well-rounded business catalyst who understands all facets of developing, producing, and sustaining long term results in the pharmaceutical/biotech marketplace.  He built his career foundation in a large Pharmaceutical company environment at Schering-Plough and then Merck & Co., and more recently has worked with a number of start-up biopharma organizations helping lead their development and commercialization/go-to-market strategies. He has a diverse background with more than 28 years in the Pharmaceutical Industry with experience in Global General Management, Marketing, Sales, Business Development, Finance, and Market Access. 
Brian Longstreet - Chief Commercial Officer
His broad therapeutic expertise includes Cardiovascular Disease, Oncology, Immunology, Infectious Disease, Diabetes, Allergy/Respiratory, Women’s Health, & Central Nervous System Disorders.  He has helped develop and launch more than 40 products over his career in both the Primary Care and Specialty arenas.  He graduated from the University of Pennsylvania’s Wharton School of Business with a Bachelor of Science degree in Economics with a concentration in Marketing. 
Evrys logo_FIN (003).png
Evrys Bio antivirals engage the cell’s own immunity to naturally defend against viral infection without the emergence of drug resistance. Based on research originating at Princeton University, Evrys products will transform medical practice by offering treatment options effective against most if not all viruses capable of causing a given infection condition; e.g., all viral hepatitis, as opposed to traditional vaccines and antiviral drugs that target a specific virus, hepatitis B or C virus, but not both.
Company Presenter
Lillian is President & CEO of Evrys Bio, a biotech start-up developing Next Gen Antivirals. Evrys is Lillian’s third foray as a member of the founding team, also, Kadmon Corporation (VP Translational Medicine) and Aestus Therapeutics (CSO). Across her three start-ups, she has successfully obtained SBIR and other non-dilutive resources from NIAID, NCI, NINDS, DoD, and NJ State. Previously, she had built from scratch state-of-the-art technologies and drug discovery teams, at Stanford, Millennium Pharmaceuticals, and Purdue Pharma. Her array technology platform was central in Millennium’s $218 and $465 M collaborations with Monsanto and Bayer, respectively. At Purdue she staffed and directed the Molecular Biology Department from scratch. As CSO at Aestus, she applied her own data mining algorithms to identify drug-repositioning assets to acquire and develop in a virtual pharma environment. It was while at Aestus that Lillian simultaneously completed her MBA at Wharton. B.S., MIT; PhD, U. Wisconsin; Postdoc, Stanford.
Lillian Chiang, Ph.D, MBA - President and CEO

Website by IQnection, proud marketing and website sponsor for HepB Gala.org.